Jul 23, 2015 by Brian Orelli, PhDBristol-Myers Squibb Gets a Mixed Message From InvestorsThe pharma beats expectations, but investors don't seem to care.
Jul 23, 2015 by Brian Orelli, PhDCelgene Rolling Along (but You Already Knew That)After pre-releasing revenue and sales numbers last week, investors got more details on the biotech's second-quarter earnings.
Jul 22, 2015 by Brian Orelli, PhDNatus Medical: This Baby Keeps GrowingEarnings grow faster than revenue as the medical-device maker increases margins.
Jul 21, 2015 by Brian Orelli, PhDBig Week for BiogenClinical trial data and earnings! What more could an investor ask for?
Jul 21, 2015 by Brian Orelli, PhDCelgene Buys Receptos. Is Arena Pharmaceuticals Next?Both biotechs have S1P1 receptor drugs, but they're not created equal.
Jul 20, 2015 by Brian Orelli, PhDExelixis' Meteroric Rise From the AshesThe biotech finally gets a positive clinical trial result in a decently sized market.
Jul 19, 2015 by Brian Orelli, PhDListening to Yellen Cost You 80%"Stretched" valuations in biotech? No, not really
Jul 8, 2015 by Brian Orelli, PhDCelgene Paid $93 Per Share for Juno, but You're Only Willing to Pay $50?The devil is in the details.
Jul 7, 2015 by Brian Orelli, PhDBiogen Sees Promise in Gene TherapyMultiple programs are in development.
Jul 6, 2015 by Brian Orelli, PhDGilead Sciences Spent $125 Million to Get This Drug on the Market 4 Months EarlyIt's all about the switching.
Jun 30, 2015 by Brian Orelli, PhDCelgene Gives Juno Therapeutics a Big Hand UpYou paid $1 billion for what?
Jun 21, 2015 by Brian Orelli, PhDInvestors Beware: Drugmakers LieAn FDA study reveals that drugmakers often don't tell the whole story about why their drugs were rejected.
Jun 16, 2015 by Brian Orelli, PhD7 Supreme Court Quotes on Obamacare You Need to HearRead these before the decision is handed down.
Jun 13, 2015 by Brian Orelli, PhD, Sean Williams, and Cheryl Swanson1 Drug Will Make or Break These 3 Biotech StocksOur experts weigh in.
Jun 8, 2015 by Brian Orelli, PhD, Sean Williams, and Cheryl Swanson3 Big Pharma Dividend Stocks That Are Dragging Down Your ReturnsOur experts weigh in.
Jun 3, 2015 by Brian Orelli, PhDYour Biotech Could Be a Buyout Target -- But Don't Bet on ItIt doesn't really matter what the CEO of a major pharmaceutical company says.
May 16, 2015 by Brian Orelli, PhDOrexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful DrugmakerA double dose of bad news for the obesity drugmaker.
May 8, 2015 by Brian Orelli, PhDAlnylam Pharmaceuticals, Inc.'s Five-Year PlanThe biotech updated investors on its Alnylam 2020 plan during its first-quarter earnings announcement.
May 7, 2015 by Brian Orelli, PhDEmergent BioSolutions Inc: No Harm, No FoulDespite a rocky first quarter, Emergent BioSolutions believes it can meet its 2015 guidance.
